As­traZeneca gets in on RNA game with Mi­NA re­search col­lab­o­ra­tion

Two months af­ter No­var­tis spent near­ly $10 bil­lion on The Med­i­cines Com­pa­ny’s RNA-based cho­les­terol drug, As­traZeneca will try to co-de­vel­op its own RNA-based meta­bol­ic ther­a­py.

The Eu­ro­pean drug­mak­er has part­nered with Mi­NA Ther­a­peu­tics to de­vel­op small ac­ti­vat­ing RNA (saR­NA) for meta­bol­ic dis­eases. The agree­ment gives As­traZeneca the right to ne­go­ti­ate a li­cens­ing agree­ment af­ter a se­ries of pre­clin­i­cal stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER